

## REMARKS

Remarks made in the October 26, 2006 Amendment are considered relevant and considered to be of record. They are not repeated herein. The October 26, 2006 claim listing was not entered. Hence changes and status indicators are shown based on the March 16, 2006 claim listing. The present claim listing differs from the October 26, 2006 claim listing at claims 8, 14 and 15.

By this amendment, claims 5, 8 and 9 are amended. Support can be found in the specification in the claims as originally filed and in the specification, for example, at paragraphs 20-22. There is no new matter. Entry of these amendments is deemed proper.

### **Amendment Compliance**

The Advisory Action indicated that the claim listing was non-compliant. Proper versions of claims 14 and 15 are found in the present claim listing. Status of claim 8 is now deemed proper. Entry of the present amendment is respectfully requested.

### **Rejections withdrawn**

Applicants gratefully acknowledge the Examiner's indication in the November 11, 2006 Advisory Action that the amendment proposed (not entered) and now entered as a matter of right would overcome the 35 U.S.C. §112 rejections.

### **Matter Requiring Further Consideration**

The November 11, 2006 Advisory Action indicated that the newly incorporated limitation regarding the zyxin derivative would minimally require further search and consideration. Such further search and consideration is respectfully requested.

### ***Concluding Remarks***

The Commissioner is authorized to charge any fees under 37 C.F.R. §1.17(r) or credit any overpayment to Account No. 18-1982.

Applicants respectfully submit that the application is now in condition for allowance and request prompt issuance of a Notice of Allowance indicating such. Should the

Examiner believe that an interview could put this application in even better condition for allowance, Applicants invite her to contact the undersigned at 908-231-3776.

Respectfully submitted,

A handwritten signature in cursive script that reads "George S. Jones". The signature is written in dark ink and is positioned above a horizontal line.

---

George S. Jones, Reg. No. 38,508  
Attorney for Applicants

sanofi-aventis  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, NJ 08807-0800  
Telephone (908) 231-3776  
Telefax (908) 231-2626  
Aventis Docket No. DEAV2000/A051 US NP